Codium fragile Ameliorates High-Fat Diet-Induced Metabolism by Modulating the Gut Microbiota in Mice

Nutrients. 2020 Jun 21;12(6):1848. doi: 10.3390/nu12061848.

Abstract

Codium fragile (CF) is a functional seaweed food that has been used for its health effects, including immunostimulatory, anti-inflammatory, anti-obesity and anti-cancer activities, but the effect of CF extracts on obesity via regulation of intestinal microflora is still unknown. This study investigated anti-obesity effects of CF extracts on gut microbiota of diet-induced obese mice. C57BL/6 mice fed a high-fat (HF) diet were given CF extracts intragastrically for 12 weeks. CF extracts significantly decreased animal body weight and the size of adipocytes, while reducing serum levels of cholesterol and glucose. In addition, CF extracts significantly shifted the gut microbiota of mice by increasing the abundance of Bacteroidetes and decreasing the abundance of Verrucomicrobia species, in which the portion of beneficial bacteria (i.e., Ruminococcaceae, Lachnospiraceae and Acetatifactor) were increased. This resulted in shifting predicted intestinal metabolic pathways involved in regulating adipocytes (i.e., mevalonate metabolism), energy harvest (i.e., pyruvate fermentation and glycolysis), appetite (i.e., chorismate biosynthesis) and metabolic disorders (i.e., isoprene biosynthesis, urea metabolism, and peptidoglycan biosynthesis). In conclusion, our study showed that CF extracts ameliorate intestinal metabolism in HF-induced obese mice by modulating the gut microbiota.

Keywords: Codium fragile; gut microbiota; high-fat diet; intestinal metabolism; obesity.

MeSH terms

  • Adipocytes / metabolism
  • Animals
  • Anti-Obesity Agents / pharmacology*
  • Anti-Obesity Agents / therapeutic use
  • Appetite
  • Bacteria / drug effects
  • Biological Products / pharmacology*
  • Biological Products / therapeutic use
  • Blood Glucose / metabolism
  • Body Weight / drug effects
  • Chlorophyta*
  • Cholesterol / blood
  • Diet, High-Fat / adverse effects*
  • Dietary Fats / adverse effects
  • Gastrointestinal Microbiome / drug effects*
  • Intestines / drug effects*
  • Intestines / microbiology
  • Male
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / metabolism
  • Metabolic Diseases / microbiology
  • Metabolic Networks and Pathways
  • Mice, Inbred C57BL
  • Mice, Obese
  • Obesity / drug therapy
  • Obesity / metabolism
  • Obesity / microbiology*
  • Seaweed

Substances

  • Anti-Obesity Agents
  • Biological Products
  • Blood Glucose
  • Dietary Fats
  • Cholesterol